Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8

– Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial

– AMT-101 appeared safe and well-tolerated

– Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

Total
0
Shares
Related Posts
Read More

Google’s $1.1B Boost For Finnish AI Data Center: Details

Alphabet Inc's Google will invest an additional €1 billion in its Finland data center campus to enhance AI capabilities in Europe. This investment supports Google's commitment to sustainable technology, leveraging Finland's renewable energy. The Hamina facility, operating with 97% carbon-free energy, will also boost local employment and contribute excess heat to the community's district heating network, benefiting public infrastructure.

GOOGL